Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Johnson & Johnson a Buy?

TheMotleyFool

0 0

Is Johnson & Johnson a Buy?Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Johnson & Johnson (NYSE: JNJ) is a blue-chip pharma stock with annual revenues in the neighborhood of $80 billion -- and that's before considering the potential of its coronavirus vaccine candidate, JNJ-78436735. What's more, it has several other multibillion-dollar opportunities coming out of its research and development (R&D) pipeline in the next few years.

Yet Johnson & Johnson did not perform as well as the S&P 500 over the past year. Indeed, the company stock only returned 12% compared to the index's 16% gain. But could the healthcare giant beat the market in 2021?